206. 脆弱Ｘ症候群 Disease details / Clinical trials / Drug dev / DR info

11C-flumazenil
   University Antwerp
      2008   -   EUCTR2008-003287-18-BE   Belgium;
18F-FTC-146
   Guido A. Davidzon, MD, MS
      2021   Phase 1   NCT04314856   United States;
5-Hydroxytryptophan / Vitamin B6
   Elizabeth Berry-Kravis
      2021   Phase 2   NCT05030129   -
ACIDUM ASCORBICUM D6
   Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
      2016   Phase 3   EUCTR2015-005460-42-ES   Spain;
AF056
   Novartis
      2008   Phase 2   NCT00718341   France;Italy;Switzerland;
AFQ056
   Elizabeth Berry-Kravis
      2017   Phase 2   NCT02920892   United States;
   NOVARTIS FARMA
      2012   -   EUCTR2011-002379-40-IT   Australia;Belgium;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2011   -   EUCTR2011-001952-12-IT   Australia;Canada;Denmark;Germany;Italy;Spain;Switzerland;United Kingdom;United States;
      2011   -   EUCTR2010-022638-96-IT   Australia;Denmark;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2010   -   EUCTR2009-013667-19-IT   Denmark;Germany;Italy;Spain;United Kingdom;
      2008   -   EUCTR2007-005088-82-IT   France;Italy;
   Novartis Farmacéutica S.A
      2012   Phase 2   EUCTR2011-001952-12-ES   Australia;Canada;Denmark;France;Germany;Italy;Spain;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2011-002379-40-ES   Australia;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2011   Phase 2   EUCTR2010-022638-96-ES   Australia;Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2011   -   EUCTR2009-013667-19-ES   Australia;Canada;Denmark;France;Germany;Italy;Spain;Switzerland;United Kingdom;United States;
   Novartis Farmacéutica, S.A.
      2012   -   EUCTR2011-004867-65-ES   Spain;United States;
   Novartis Pharma Services AG
      2013   Phase 2   EUCTR2011-002379-40-BE   Australia;Belgium;Brazil;Canada;Denmark;France;Germany;Indonesia;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 2   EUCTR2010-022638-96-BE   Australia;Belgium;Brazil;Canada;Denmark;France;Germany;Indonesia;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2011-002379-40-NL   Australia;Brazil;Canada;Denmark;France;Germany;Indonesia;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2010-022638-96-NL   Australia;Brazil;Canada;Denmark;France;Germany;Indonesia;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 2   EUCTR2011-002379-40-GB   Australia;Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2012   Phase 2   EUCTR2011-002379-40-FR   Australia;Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2012   Phase 2   EUCTR2011-002379-40-DK   Australia;Belgium;Brazil;Canada;Denmark;France;Germany;Indonesia;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 2   EUCTR2011-001952-12-FR   Australia;Canada;Denmark;France;Germany;Italy;Spain;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2011-002379-40-SE   Australia;Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2011-002379-40-DE   Australia;Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2011   Phase 2   EUCTR2011-001952-12-GB   Australia;Canada;Denmark;France;Germany;Italy;Spain;Switzerland;United Kingdom;United States;
      2011   Phase 2   EUCTR2010-022638-96-GB   Australia;Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2011   -   EUCTR2011-001952-12-DK   Australia;Canada;Denmark;France;Germany;Italy;Spain;Switzerland;United Kingdom;United States;
      2011   -   EUCTR2011-001952-12-DE   Australia;Canada;Denmark;France;Germany;Italy;Spain;Switzerland;United Kingdom;United States;
      2011   -   EUCTR2010-022638-96-SE   Australia;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2011   -   EUCTR2010-022638-96-DK   Australia;Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2010   Phase 2   EUCTR2009-013667-19-GB   Australia;Canada;Denmark;France;Germany;Italy;Spain;Switzerland;United Kingdom;United States;
      2010   -   EUCTR2009-013667-19-DK   Australia;Canada;Denmark;France;Germany;Italy;Spain;Switzerland;United Kingdom;United States;
      2010   -   EUCTR2009-013667-19-DE   Australia;Canada;Denmark;France;Germany;Italy;Spain;Switzerland;United Kingdom;United States;
      2008   -   EUCTR2007-005088-82-FR   France;Italy;
      -   Phase 2   EUCTR2010-022638-96-FR   Australia;Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      -   -   EUCTR2011-004867-65-Outside-EU/EEA   Spain;United States;
      -   -   EUCTR2011-002379-40-Outside-EU/EEA   Australia;Switzerland;United States;
      -   -   EUCTR2010-022638-96-Outside-EU/EEA   Australia;United States;
      -   -   EUCTR2010-022638-96-DE   Australia;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      -   -   EUCTR2010-019353-18-Outside-EU/EEA   Switzerland;
   Novartis Pharmaceuticals
      2012   Phase 1   NCT01482143   Spain;Switzerland;United States;
      2011   Phase 2/Phase 3   NCT01433354   Australia;Belgium;Brazil;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2011   Phase 2   NCT01357239   Australia;Belgium;Brazil;Canada;Denmark;France;Germany;Indonesia;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2011   Phase 2   NCT01348087   Australia;Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
      2010   Phase 2   NCT01253629   Australia;Canada;Denmark;France;Germany;Italy;Spain;Switzerland;United Kingdom;United States;
AZD7325 (High-Dose)
   Children's Hospital Medical Center, Cincinnati
      2018   Phase 1   NCT03140813   United States;
AZD7325 (Low-Dose)
   Children's Hospital Medical Center, Cincinnati
      2018   Phase 1   NCT03140813   United States;
Acamprosate
   Children's Hospital Medical Center, Cincinnati
      2016   Early Phase 1   NCT02998151   United States;
      2013   Phase 1   NCT01911455   United States;
   Indiana University
      2010   Phase 2   NCT01300923   United States;
Arbaclofen
   Seaside Therapeutics, Inc.
      2011   Phase 3   NCT01555333   United States;
      2011   Phase 3   NCT01325220   United States;
      2011   Phase 3   NCT01282268   United States;
      2009   Phase 2   NCT01013480   United States;
Aripiprazole
   Indiana University School of Medicine
      2007   Phase 2   NCT00420459   United States;
Ascorbic Acid (Vitamin C) and Alpha-tocopherol (Vitamin E)
   Yolanda de Diego Otero
      2010   Phase 2   NCT01329770   Spain;
BPN14770
   Tetra Discovery Partners
      2018   Phase 2   NCT03569631   United States;
Baclofen
   Children's Hospital Medical Center, Cincinnati
      2016   Early Phase 1   NCT02998151   United States;
CCD 1042, MD 9150000, Mepalon 1042, SPT316
   Antwerp University Hospital
      2014   -   EUCTR2014-000251-89-BE   Belgium;United States;
CX516 (Ampalex®)
   Cortex Pharmaceuticals
      2002   Phase 2   NCT00054730   United States;
Donepezil
   Stanford University
      2009   Phase 2   NCT01120626   United States;
      2005   Phase 1   NCT00220584   United States;
EGCG
   Parc de Salut Mar
      2013   Phase 2   NCT01855971   Spain;
EGCG FontUp
   Parc de Salut Mar
      2018   -   NCT03624556   Spain;
Ganaxolone
   Marinus Pharmaceuticals
      2012   Phase 2   NCT01725152   Belgium;United States;
Lovastatin
   Children's Hospital Medical Center, Cincinnati
      2016   Early Phase 1   NCT02998151   United States;
   University of California, Davis
      2016   Phase 4   NCT02642653   United States;
Lovastatin, then Minocycline/Lovastatin
   Université de Sherbrooke
      2016   Phase 2   NCT02680379   Canada;
MG01CI extended-release tablet
   Alcobra Ltd.
      2014   Phase 2   NCT02126995   Israel;United States;
MGlu5 antagonist
   F. Hoffmann-La Roche Ltd.
      2012   Phase 2   EUCTR2011-004349-42-GB   Argentina;Canada;Chile;France;Mexico;Peru;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2011-004349-42-SE   Argentina;Canada;Chile;France;Mexico;Peru;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2011-004349-42-ES   Argentina;Canada;Chile;France;Mexico;Peru;Spain;Sweden;United Kingdom;United States;
Mavoglurant
   Novartis Pharma Services AG
      2013   Phase 2   EUCTR2011-002379-40-BE   Australia;Belgium;Brazil;Canada;Denmark;France;Germany;Indonesia;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 2   EUCTR2010-022638-96-BE   Australia;Belgium;Brazil;Canada;Denmark;France;Germany;Indonesia;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2011-002379-40-NL   Australia;Brazil;Canada;Denmark;France;Germany;Indonesia;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2010-022638-96-NL   Australia;Brazil;Canada;Denmark;France;Germany;Indonesia;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      -   -   EUCTR2010-022638-96-Outside-EU/EEA   Australia;United States;
      -   -   EUCTR2010-019353-18-Outside-EU/EEA   Switzerland;
Metformin
   Children's Hospital of Fudan University
      2021   Phase 4   NCT05120505   China;
   Rowan University
      2019   Phase 1/Phase 2   NCT04141163   United States;
   University of Alberta
      2019   Phase 2   NCT03862950   Canada;
   University of California, Davis
      2018   Phase 2/Phase 3   NCT03479476   United States;
   Université de Sherbrooke
      2018   Phase 2   NCT03722290   Canada;
Methylphenidate, fluoxetin, risperidone
   The Chaim Sheba Medical Center
      2001   Phase 4   NCT00768820   Israel;
Minocycline
   Children's Hospital Medical Center, Cincinnati
      2016   Early Phase 1   NCT02998151   United States;
   FRAXA Research Foundation
      2007   -   NCT00858689   Canada;
Minocycline hydrochloride
   University of California, Davis
      2010   -   NCT01053156   United States;
Minocycline, then Minocycline/Lovastatin
   Université de Sherbrooke
      2016   Phase 2   NCT02680379   Canada;
NNZ-2566
   Neuren Pharmaceuticals Limited
      2014   Phase 2   NCT01894958   United States;
NPL-2009
   Neuropharm
      2008   Phase 1/Phase 2   NCT00637221   United States;
OV101
   Ovid Therapeutics Inc.
      2017   Phase 1   NCT03109756   United States;
OV101 (gaboxadol)
   Ovid Therapeutics Inc.
      2018   Phase 2   NCT03697161   United States;
Oxytocin 24IU
   Stanford University
      2007   Phase 2   NCT01254045   United States;
Oxytocin 48IU
   Stanford University
      2007   Phase 2   NCT01254045   United States;
RO4917523
   Hoffmann-La Roche
      2013   Phase 2   NCT01750957   United States;
      2012   Phase 2   NCT01517698   Argentina;Canada;Chile;France;Mexico;Peru;Spain;Sweden;United Kingdom;United States;
      2009   Phase 2   NCT01015430   United States;
Riluzole
   Indiana University
      2009   Phase 4   NCT00895752   United States;
Ro 491-7523/F18
   F. Hoffmann-La Roche Ltd.
      2012   Phase 2   EUCTR2011-004349-42-GB   Argentina;Canada;Chile;France;Mexico;Peru;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2011-004349-42-SE   Argentina;Canada;Chile;France;Mexico;Peru;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2011-004349-42-ES   Argentina;Canada;Chile;France;Mexico;Peru;Spain;Sweden;United Kingdom;United States;
Ro 491-7523/F19
   F. Hoffmann-La Roche Ltd.
      2012   Phase 2   EUCTR2011-004349-42-GB   Argentina;Canada;Chile;France;Mexico;Peru;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2011-004349-42-SE   Argentina;Canada;Chile;France;Mexico;Peru;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2011-004349-42-ES   Argentina;Canada;Chile;France;Mexico;Peru;Spain;Sweden;United Kingdom;United States;
STX107
   Seaside Therapeutics, Inc.
      2011   Phase 2   NCT01325740   United States;
      2009   Phase 1   NCT00965432   United States;
STX209
   Seaside Therapeutics, Inc.
      2009   -   NCT00892580   United States;
      2009   -   NCT00823368   United States;
      2008   Phase 2   NCT00788073   United States;
Sertraline
   Randi J. Hagerman, MD
      2012   Phase 2   NCT01474746   United States;
Sugar pill
   Stanford University
      2009   Phase 2   NCT01120626   United States;
Sulindac, dose strength 1
   Healx Limited
      2022   Phase 2   NCT04823052   United States;
Sulindac, dose strength 2
   Healx Limited
      2022   Phase 2   NCT04823052   United States;
Vitamin C
   Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
      2016   Phase 3   EUCTR2015-005460-42-ES   Spain;
Vitamin C 10mg/Kg Vitamin E
   Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
      2016   Phase 3   NCT02942498   Spain;
Vitamin E
   Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
      2016   Phase 3   EUCTR2015-005460-42-ES   Spain;
ZYN002
   Zynerba Pharmaceuticals, Inc.
      -   Phase 3   EUCTR2021-002542-33-IE   Australia;Ireland;United Kingdom;United States;
ZYN002 - CBD Transdermal Gel
   Zynerba Pharmaceuticals, Inc.
      2018   Phase 2/Phase 3   NCT03802799   Australia;New Zealand;United States;
      2018   Phase 2/Phase 3   NCT03614663   Australia;New Zealand;United States;
ZYN002 - transdermal gel
   Zynerba Pharmaceuticals, Inc.
      2021   Phase 3   NCT04977986   Australia;Ireland;United Kingdom;United States;
Zatolmilast
   Tetra Discovery Partners
      2021   Phase 2/Phase 3   NCT05163808   -
[18F]FPEB
   Institute for Neurodegenerative Disorders
      2009   Phase 1   NCT00870974   United States;
[18F]FPEB PET imaging
   University Hospital, Tours
      2016   Phase 1   NCT02719951   France;
[18F]flumazenil
   Stanford University
      2016   Phase 1   NCT04308954   United States;